GLP-1 Medications List: Ingredients, Brands, Forms, Uses, and Frequency

“GLP-1 medications” is often used as a broad label for medicines that activate the GLP-1 receptor, plus tirzepatide, which activates both GIP and GLP-1 receptors. The ingredient and the brand matter more than the category name. This US-oriented list reflects prescribing information checked on October 26, 2026; products and indications can change, so verify the current label before making a treatment decision.

Quick reference: a summary of selected labeled uses

This table is deliberately compact. The entries summarize labeled uses; they do not reproduce all eligibility conditions, and frequency is not dosing advice. “Eligible adults” for weight management generally means adults with obesity, or overweight plus a weight-related condition, under the product’s own criteria. The exact label controls eligibility, titration, missed-dose instructions, contraindications, and warnings.

Wegovy’s MASH indication applies to the injection, not the tablet. It concerns adults with noncirrhotic metabolic dysfunction-associated steatohepatitis and moderate-to-advanced liver fibrosis, and was granted through accelerated approval based on improvement in MASH and fibrosis. Continued approval may depend on confirmation of clinical benefit. A shared brand name does not make the indications for its different forms identical.

The Wegovy label, Mounjaro label, Zepbound label, and Foundayo label are the primary sources for those rows. Other rows follow the linked product labels below.

Generic liraglutide products also appear in US labeling. Check the exact manufacturer’s label and intended indication rather than treating “generic liraglutide” as a single product description. For example, the Teva liraglutide label checked for this article is for weight management. The ingredient name alone does not tell you whether a particular pen is the product your clinician intended.

Older names and products containing insulin

Older GLP-1 lists may also include exenatide (Byetta or extended-release Bydureon/Bydureon BCise) and lixisenatide (Adlyxin). Their place in the class is not a promise that a particular brand is currently marketed or in stock. A historical label, a current approval, and pharmacy availability are three different things. Ask a pharmacist to verify availability of the exact presentation before using an older list to plan treatment.

The historical label frequency is twice daily for Byetta, an exenatide injection for type 2 diabetes in adults, and once daily for Adlyxin, a lixisenatide injection for the same broad purpose. These are product-label descriptions, not verification that either exact presentation is currently supplied. Availability of extended-release exenatide products was not established in this check.

Two combination products also contain a GLP-1 receptor agonist:

These are insulin-containing products, not another version of a weight-management GLP-1 prescription. Their administration, monitoring, and hypoglycemia considerations follow their own labels: Soliqua and Xultophy.

How to read the list

Ingredient and brand are different fields. The combined Rybelsus/Ozempic tablet row names two distinct products; grouping them for reference does not make them interchangeable. Ozempic and Rybelsus contain semaglutide but are not interchangeable by milligram. Mounjaro and Zepbound both contain tirzepatide, but their approved uses and evidence populations differ. Victoza and Saxenda both contain liraglutide, with different labeled purposes.

Form changes the routine. Injections may be weekly or daily. Oral products may have timing instructions that are part of how the medicine works. For example, the combined Rybelsus and Ozempic tablet label instructs taking the tablet in the morning on an empty stomach with up to 4 ounces of water, swallowing it whole, and waiting at least 30 minutes before eating, drinking, or taking another oral medicine. The tablets must not be split, crushed, chewed, or dissolved. Foundayo’s label, in contrast, permits taking it with or without food. That is a product-specific instruction, not a general rule for every tablet.

A research name is not another approved option. Retatrutide belongs in a discussion of triple-agonist research, not an automatic extra row in an approved-product table. Supplements marketed with “GLP-1” language are also not the same as prescription GLP-1 receptor agonists.

Approval is not the same as suitability. A medicine can be approved for an indication without being appropriate for every person with that condition. Medical history, other medicines, pregnancy plans, kidney or gastrointestinal problems, and contraindications can change the conversation. Compounded or investigational products should not be silently added to an “approved medications” list.

Questions to take to a clinician or pharmacist

Ask which ingredient and brand are being discussed, which indication applies, how the form fits your routine, what monitoring is needed, and which label warnings matter for your history. Ask how to handle a missed dose rather than improvising. If you are comparing two products, compare their current labels and evidence populations side by side; do not choose by brand familiarity or by a list’s position.

A medication list is most useful as a map. It helps you identify the exact product and the next question. It cannot decide which prescription is right for you.

Product labels for further checking

• Ozempic injection
• Rybelsus and Ozempic tablets
• Victoza
• Saxenda
• Trulicity
• Adlyxin

For the broader difference between oral and injectable routines, see GLP-1 pills versus injections. This list identifies products; it does not rank them or replace a personal eligibility assessment.